| Dr Vi Thao Nguyen, OD | |
|
1040 Cypress Pkwy, Kissimmee, FL 34759-3328 | |
| (407) 654-5453 | |
| Not Available |
| Full Name | Dr Vi Thao Nguyen |
|---|---|
| Gender | Female |
| Speciality | Optometrist |
| Location | 1040 Cypress Pkwy, Kissimmee, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346760204 | NPI | - | NPPES |
| OPC5415 | Other | FL | FLORIDA OPTOMETRY LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | OPC5415 (Florida) | Primary |
| Provider Name | Myeyedr Optometry Of Florida, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1073907028 PECOS PAC ID: 0143541037 Enrollment ID: O20150603002802 |
News Archive
Otsuka Pharmaceutical Co., Ltd. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Deltyba (delamanid) in combination with a WHO recommended optimized background regimen for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB). The CHMP opinion will help form the basis for a European Commission decision expected early next year.
Certain diseases, like Parkinson's and Huntingdon's disease, are associated with damage to the pathways between the brain's basal ganglia regions. The basal ganglia sits at the base of the brain and is responsible for, among other things, coordinating movement. It is made up of four interconnected, deep brain structures that imaging techniques have previously been unable to visualize.
The number of bacteria living within the body of the average healthy adult human are estimated to outnumber human cells 10 to 1. Changes in these microbial communities may be responsible for digestive disorders, skin diseases, gum disease and even obesity.
ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2011.
Medicines for Malaria Venture has outlined a $600 million, five-year plan to develop new malaria drugs, SciDev.net reports. The plan was launched in conjunction with the release last week of the Global Malaria Action Plan, which aims to eradicate malaria worldwide.
› Verified 6 days ago
| Provider Name | Thanh & Vi Eye Care |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1457975856 PECOS PAC ID: 8325463094 Enrollment ID: O20200729001835 |
News Archive
Otsuka Pharmaceutical Co., Ltd. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Deltyba (delamanid) in combination with a WHO recommended optimized background regimen for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB). The CHMP opinion will help form the basis for a European Commission decision expected early next year.
Certain diseases, like Parkinson's and Huntingdon's disease, are associated with damage to the pathways between the brain's basal ganglia regions. The basal ganglia sits at the base of the brain and is responsible for, among other things, coordinating movement. It is made up of four interconnected, deep brain structures that imaging techniques have previously been unable to visualize.
The number of bacteria living within the body of the average healthy adult human are estimated to outnumber human cells 10 to 1. Changes in these microbial communities may be responsible for digestive disorders, skin diseases, gum disease and even obesity.
ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2011.
Medicines for Malaria Venture has outlined a $600 million, five-year plan to develop new malaria drugs, SciDev.net reports. The plan was launched in conjunction with the release last week of the Global Malaria Action Plan, which aims to eradicate malaria worldwide.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Vi Thao Nguyen, OD 7595 Blue Quail Ln, Orlando, FL 32835-5808 Ph: (407) 731-9638 | Dr Vi Thao Nguyen, OD 1040 Cypress Pkwy, Kissimmee, FL 34759-3328 Ph: (407) 654-5453 |
News Archive
Otsuka Pharmaceutical Co., Ltd. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Deltyba (delamanid) in combination with a WHO recommended optimized background regimen for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB). The CHMP opinion will help form the basis for a European Commission decision expected early next year.
Certain diseases, like Parkinson's and Huntingdon's disease, are associated with damage to the pathways between the brain's basal ganglia regions. The basal ganglia sits at the base of the brain and is responsible for, among other things, coordinating movement. It is made up of four interconnected, deep brain structures that imaging techniques have previously been unable to visualize.
The number of bacteria living within the body of the average healthy adult human are estimated to outnumber human cells 10 to 1. Changes in these microbial communities may be responsible for digestive disorders, skin diseases, gum disease and even obesity.
ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2011.
Medicines for Malaria Venture has outlined a $600 million, five-year plan to develop new malaria drugs, SciDev.net reports. The plan was launched in conjunction with the release last week of the Global Malaria Action Plan, which aims to eradicate malaria worldwide.
› Verified 6 days ago
Florida Optical Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1011 W Vine St, Kissimmee, FL 34741 Phone: 407-862-7699 Fax: 407-862-9672 | |
Eye Deal Optical Llc Optometrist Medicare: Medicare Enrolled Practice Location: 1204 N John Young Pkwy, Kissimmee, FL 34741 Phone: 407-933-0082 Fax: 407-933-0086 | |
Dr. S.j. Manikowski, O.d., P.a. & Associates Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3272 N John Young Pkwy, Kissimmee, FL 34741 Phone: 407-870-0051 | |
Eye Doctors Optical Outlets Pa Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1150 E Vine St, Kissimmee, FL 34744 Phone: 813-885-3937 | |
Mrs. Michelle Esperanza, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1471 E Osceola Pkwy, Kissimmee, FL 34744 Phone: 407-799-7281 Fax: 407-870-0747 | |
Dr. Becky Crockett, OD Optometrist Medicare: Medicare Enrolled Practice Location: 921 N Main St, Kissimmee, FL 34744 Phone: 407-933-7800 Fax: 407-933-8657 | |
Susan A Driscoll, O.d.,llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3272 N John Young Pkwy, Kissimmee, FL 34741 Phone: 407-870-0051 |